SEC Filing Summary: Graphite Bio, Inc. (GRPH)
Business Context and Reporting Period
This Form 8-K was filed by Graphite Bio, Inc. on August 12, 2021. The filing serves to announce the company's financial results for the second quarter ended June 30, 2021. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in South San Francisco, CA.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were announced via a press release (Exhibit 99.1) but does not embed the financial data within the 8-K text itself.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in this specific filing text. The filing references the Q2 2021 results but does not provide the comparative figures necessary to identify changes.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information contained in the report and the accompanying press release exhibit shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 12, 2021) for actual Q2 2021 financial figures.
- Verify the company's cash position and burn rate, as these are not listed in the 8-K text.
- Confirm any updates to the company's clinical pipeline or operational milestones mentioned in the referenced press release.
- Note that the 8-K text explicitly disclaims incorporation by reference for the financial data.